Research ArticleOpen AccessGoogle Scholar indexed

Sorafenib after Arterial Chemoembolization in Child-Pugh A and B Cirrhotic Patients with Intermediate Hepatocellular Carcinoma: A Retrospective Analysis

¹ Gastroenterology Division, Department of Internal Medicine, Faculdade de Medicina de Botucatu, UNESP—Univ Estadual Paulista, Sao Paulo, Brazil
² Faculdade de Medicina de Botucatu, UNESP—Univ Estadual Paulista, Sao Paulo, Brazil
³ Department of Physics and Biophysics, Instituto de Biociências de Botucatu, UNESP—Univ Estadual Paulista, Sao Paulo, Brazil
⁴ Gastroenterology Division, Department of Internal Medicine, Faculdade de Medicina de Botucatu, UNESP—Univ Estadual Paulista, Sao Paulo, Brazil
⁵ Gastroenterology Division, Department of Internal Medicine, Faculdade de Medicina de Botucatu, UNESP—Univ Estadual Paulista, Sao Paulo, Brazil
⁶ Gastroenterology Division, Department of Surgery and Orthopedics, Faculdade de Medicina de Botucatu, UNESP—Univ Estadual Paulista, Sao Paulo, Brazil
⁷ Gastroenterology Division, Department of Internal Medicine, Faculdade de Medicina de Botucatu, UNESP—Univ Estadual Paulista, Sao Paulo, Brazil
⁸ Gastroenterology Division, Department of Internal Medicine, Faculdade de Medicina de Botucatu, UNESP—Univ Estadual Paulista, Sao Paulo, Brazil
⁹ Department of Physics and Biophysics, Instituto de Biociências de Botucatu, UNESP—Univ Estadual Paulista, Sao Paulo, Brazil
¹⁰ Gastroenterology Division, Department of Internal Medicine, Faculdade de Medicina de Botucatu, UNESP—Univ Estadual Paulista, Sao Paulo, Brazil

Journal of Cancer Therapy·Volume 06 (2015)·Pages 286–292·Published 25 February 2015·DOI10.4236/jct.2015.63031

Abstract

Introduction: Hepatocellular carcinoma (HCC) is a leading cause of mortality among cirrhotic patients, and current guidelines recommend single-treatment modalities according to patient and liver disease classifications. New studies have shown promising results from combining locoregional and systemic treatments, but most of them were limited to Child-Pugh A patients due to toxicity concerns. Aim: The objective of this study was to analyze survival rates of Child-Pugh A and B patients with intermediate HCC tumors treated with transarterial chemoembolization (TACE) followed by full-dose sorafenib usage. Material and methods: a retrospective analysis of 37 cirrhotic patients (Child-Pugh A and B rates = 23/14) treated with TACE and TACE followed by sorafenib usage (17 and 20 patients, respectively). Results: The mean survival was 379 days in the combined treatment group and 151 days in the single-treatment group (p = 0.007). There were no differences in survival according to the Child-Pugh classification. Conclusions: sorafenib after TACE can be an option for selected cirrhotic patients with intermediate HCC tumors if this combined approach is cautiously performed on an individualized schedule. Our results suggest that the Child-Pugh classification should not be a limitation to this combined treatment.

KeywordsHepatocellular CarcinomaCirrhosisArterial ChemoembolizationSorafenib

Gomaa, A.I., Khan, S.A., Tolledano, M.B., Waked, I. and Taylor-Robinson, S.D. (2008) Hepatocellular Carcinoma: Epidemiology, Risk Factors and Pathogenesis. World Journal of Gastroenterology, 14, 4300-4308. http://dx.doi.org/10.3748/wjg.14.4300
Lau, W.T. and Lai, E.C.H. (2008) Hepatocellular Carcinoma: Current Management and Recent Advances. Hepatobiliary & Pancreatic Diseases International, 7, 237-257.
Ferlay, J., Shin, H.R., Bray, F., Forman, D., Mathers, C. and Parkin, D.M. (2010) Estimates of Worldwide Burden of Cancer in 2008: GLOBOCAN 2008. International Journal of Cancer, 127, 2893-2917. http://dx.doi.org/10.1002/ijc.25516
Bruix, J., Sherman, M., Llovet, J.M., Beaugrand, M., Lencioni, R., Burroughs, A.K., et al. (2001) Clinical Managementof Hepatocellular Carcinoma: Conclusions of the Barcelona-2000 EASL Conference. Journal of Hepatology, 35, 421-430. http://dx.doi.org/10.1016/S0168-8278(01)00130-1
Gomaa, A.I., Hashim, M.S. and Waked, I. (2014) Comparing Staging Systems for Predicting Prognosis and Survival in Patients with Hepatocellular Carcinoma in Egypt. PLoS One, 9, e90929. http://dx.doi.org/10.1371/journal.pone.0090929
Bruix, J., Raoul, J.L., Sherman, M., Mazzaferro, V., Bolondi, L., Craxi, A., Galle, P.R., Santoro, A., Beaugrand, M., Sangiovanni, A., Porta, C., Gerken, G., Marrero, J.A., Nadel, A., Shan, M., Moscovici, M., Voliotis, D. and Llovet, J.M. (2012) Efficacy and Safety of Sorafenib in Patients with Advanced Hepatocellular Carcinoma: Subanalyses of a Phase III Trial. Journal of Hepatology, 57, 821-829. http://dx.doi.org/10.1016/j.jhep.2012.06.014
Kudo, M. and Ueshima, K. (2010) Positioning of a Molecular-Targeted Agent, Sorafenib, in the Treatment Algorithm for Hepatocellular Carcinoma and Implication of Many Complete Remission Cases in Japan. Oncology, 78(S1), 154-166. http://dx.doi.org/10.1159/000315245
Radu, P., Groza, I., Iancu, C., Al Hajjar, N., Andreica, V. and Sparchez, Z. (2013) Treatment of Hepatocellular Carcinoma in a Tertiary Romanian Center. Deviations from BCLC Recommendations and Influence on Survival Rate. Journal of Gastrointestinal and Liver Diseases, 22, 291-297.
Sansonno, D., Lauletta, G., Russi, S., Conteduca, V., Sansonno, L. and Dammacco, F. (2012) Transarterial Chemoembolization Plus Sorafenib: A Sequential Therapeutic Scheme for HCV-Related Intermediate-Stage Hepatocellular Carcinoma: A Randomized Clinical Trial. The Oncologist, 17, 359-366. http://dx.doi.org/10.1634/theoncologist.2011-0313

Menu

Menu

Menu

Sorafenib after Arterial Chemoembolization in Child-Pugh A and B Cirrhotic Patients with Intermediate Hepatocellular Carcinoma: A Retrospective Analysis

Abstract

References (15)